| Literature DB >> 30370256 |
Kichul Yoon1,2, Nayoung Kim1,3.
Abstract
Although genetic background is known to contribute to colon carcinogenesis, the exact etiology of the disease remains elusive. The organ's extensive interaction with microbes necessitated research on the role of microbiota on development of colon cancer. In this review, we summarized the defense mechanism of colon from foreign organism, and germ-free animal models that have been employed to elucidate microbial effect. We also comprehensively discussed the metabolic property of microbiota such as butyrate production, facilitation of heme toxicity, bile acid transformation, and nitrate reduction that has been shown to contribute to the development of the tumor. Finally, up-to-date subjects such as the effect of age and gender on microbiota are briefly discussed.Entities:
Keywords: Bile acids and salts; Butyric acid; Carcinogenesis; Colon; Microbiota
Year: 2018 PMID: 30370256 PMCID: PMC6197845 DOI: 10.15430/JCP.2018.23.3.117
Source DB: PubMed Journal: J Cancer Prev ISSN: 2288-3649
Figure 1General mechanisms for microbiota-related colon cancer. Bacteria and their products affect the gut permeability to antigen. Dietary substrates undergo bacterial metabolism to form potentially carcinogenic products such as NOCs and secondary bile acids. Accordingly, chronic inflammation and genotoxicity contribute to the colon tumorigenesis. NOCs, N-nitroso compounds. Adapted from Sun and Kato.15
Figure 2Dietary compounds and the role of microbiota in colon carcinogenesis. Specific food compounds that are related to microbiota, and have a role in colon carcinogenesis, are shown. SCFAs, short-chain fatty acids; NOCs, N-nitroso compunds; ROS, reactive oxygen species. Adapted from Louis et al.29 with original copyright holder’s permission.
Key studies on butyrate and microbiota regarding colon cancer
| Author (year) | Study subject | Protocol | Effect of butyrate on colon |
|---|---|---|---|
| Whitehead et al. (1986) | Cell line LIM1215 | In vitro | Differentiating effect |
| Freeman (1986) | Wistar rats | In vivo DMH | Enhancing the development of colonic neoplasia |
| Deschner et al. (1990) | CF1 Mice | In vivo AOM | No difference in dysplasia or tumor |
| Archer et al. (1998) | Cell line HT-29 | In vitro | Growth inhibition |
| O'Keefe et al. (2009) | Human | Cross-sectional | Higher fecal butyrate in Native Africans |
| Donohoe et al. (2011) | C57BL/6 mice | Ex vivo CV vs. GF | Stimulating colon epithelial cell proliferation |
| Furusawa et al. (2013) | Mice | In vitro, in vivo | Inducing differentiation of colon Tregs |
| Belcheva et al. (2014) | APCMin/+MSH2−− mice | In vivo | Inducing aberrant proliferation and transformation |
| Singh et al. (2014) | Niacr1−− mice | In vivo, ex vivo AOM + DSS | Suppressing colon inflammation and carcinogenesis |
| Humphreys et al. (2014) | Human | Randomized trial | Restoring oncogenic miRNA to baseline |
DMH, 1,2-dimethylhydrazine; AOM, azoxymethane; CV, conventional; GF, germ-free; Tregs, regulatory T cells; DSS, dextran sulfate sodium; miRNA, microRNA.
GF IQI, C57BL/6 mice, Myd88−−Ticam1−− mice, OT-II transgenic mice.
C57BL/6J background.
C57BL/6 background.